Coronary heart disease in China

Coronary heart disease (CHD) is the second leading cause of cardiovascular death in the Chinese population. It accounts for 22% of cardiovascular deaths in urban areas and 13% in rural areas. Although mortality from CHD in China is relatively low compared with Western levels, the burden of CHD has been increasing. This is partly because of a worsening profile of risk factors, such as an increased prevalence of hypertension, hyperlipidaemia, overweight/obesity, diabetes, etc and partly because of an increase in the aged population. Large-scale, randomised controlled trials on thrombolytic, blood-pressure-lowering, antiplatelet and blood-cholesterol-lowering treatment as well as cardiac intervention have been conducted for Chinese patients with myocardial infarction. The studies provide important information for the prevention and management of chronic CHD and acute myocardial infarction in the Chinese population.

[1]  Y. Li,et al.  CHD and its risk factors in the People's Republic of China. , 1990, International journal of epidemiology.

[2]  R. Collins,et al.  Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1) , 1995, The Lancet.

[3]  Jing Liu,et al.  Sino-MONICA Project: A Collaborative Study on Trends and Determinants in Cardiovascular Diseases in China, Part I: Morbidity and Mortality Monitoring , 2001, Circulation.

[4]  A data analysis of the Third National Coronary Intervention Registry , 2002 .

[5]  M. Woodward,et al.  The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. , 2003, Diabetes care.

[6]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[7]  Jun Zhu,et al.  [Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases]. , 2005, Zhonghua yi xue za zhi.

[8]  Main Causes and Its Modifiable Risks of Death among Men and Women in China , 2006 .

[9]  Yang-feng Wu,et al.  Effect of Xuezhikang on Cardiovascular Events and Mortality in Elderly Patients with a History of Myocardial Infarction: A Subgroup Analysis of Elderly Subjects from the China Coronary Secondary Prevention Study , 2007, Journal of the American Geriatrics Society.

[10]  Ling Liu,et al.  Xuezhikang, An Extract of Cholestin, Reduces Cardiovascular Events in Type 2 Diabetes Patients With Coronary Heart Disease: Subgroup Analysis of Patients With Type 2 Diabetes From China Coronary Secondary Prevention Study (CCSPS) , 2007, Journal of cardiovascular pharmacology.